BioSpace News Archive

Hangzhou, Zhejiang, China, [December 9th, 2022], Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”) today announced that it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA), to investigate Doer Bio’s anti-Claudin18.2 antibody DR30303, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027.

Novavax, Inc. announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of shares of its common stock.

Gritstone bio, Inc. announced that the company’s Board of Directors granted five employees nonqualified stock options to purchase an aggregate of 46,950 shares of its common stock with an exercise price of $2.69, which is equal to the closing price of Gritstone’s common stock on December 6, 2022, the date of the grant.

Guardant Health, Inc., a leading precision oncology company, announced positive results from ECLIPSE, an over 20,000 patient registrational study evaluating the performance of its blood test for detecting colorectal cancer in average-risk adults.

Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on December 9, 2022, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 35 new employees under Rule 5635 of the NASDAQ Listing Rules.

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of December 2022, which is payable on January 16, 2023 to shareholders of record at the close of business on December 30, 2022.